SCCR32 Day 4 Strong statement on education by the American University PIJIP
Speaking on behalf of the American University programme on information justice and Intellectual Property. And I speak as an educator myself and also on behalf of a larger network that I coordinate called the global expert network on user rights which is a network of educators.April 28, 2016 letter regarding US Senate Finance threats over compulsory license on Novartis cancer drug patents
Update: english translation of letter now available at end this blog.
SCCR 32 KEI on Orphan Works
KEI Statement SCCR 32 Day 4 on “Orphan works” and Libraries and Archives
I will be speaking here as a user of libraries and archives and as a user of out of print and orphan works for my past academic work and my research today.
April 27, 2016 Letter from Colombian Embassy regarding Senate Finance, USTR pressure on Novartis compulsory license
Senator Hatch, before pressuring Colombia over cancer drug compulsory license, wanted one for Napster
(More on Colombia here: /colombia)
Continue ReadingFundación Karisma at WIPO SCCR32 on broadcast treaty
Good afternoon, and thank you very much, sir.
I wanted to refer to the rights to be granted in this proposed treaty and I would like to give you an example of something that has recently happened in Colombia and how sometimes the retransmission rights can be abused.2016: Dedalus Pharma, LLC, KEI comments on NIH proposal for exclusive licenses on CARs to treat cancer
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On April 22nd, 2016 the NIH posted a notice on the Federal Register stating it is contemplating the grant of an exclusive license to Dedalus… Continue Reading
KEI Comments to DHHS on WHA 69 re CEWG, Nocommunicable Diseases
Today the Department of Health and Human Services held their annual WHA listening session. This year HHS sent an email the day prior announcing that the usual 3 minute allotment would be cut in half to 90 seconds. This decision caused several NGOs to not attend.
Xtandi patient on Medicare — with supplement — pays $441.97 per month
Astellas has claimed that patients taking Xtandi face very small co-payments. One patient living in Arizona contacted KEI with proof that Astellas’ claims just aren’t true. The patient, who is on Medicare, provided a copy of a summary of his expenses for the first quarter of of 2016.
His monthly patient co-payment is $441.97 a month.
2016: KEI objections to NIH licenses to Vital Spark, Kalytera Therapeutics, CB1 receptor mediating compounds
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) May 4, 2016 Betty Tong, Ph.D. Senior Licensing and Patenting Manager Technology Advancement Office National Institute of Diabetes and Digestive and Kidney Diseases 12A South… Continue Reading
